EVALUATION FORM 2A
For therapies that are not likely to be curative with primary endpoint of OS

Name of study: 

Study medicine: Indication: 

First author: Year: Journal: 

Name of evaluator: 

If median OS with the standard treatment $\geq$36 months or not reached with $\geq$36 months follow-up

Mark with X if relevant

**GRADE 4**
HR $\leq$0.70 AND gain $\geq$12 months

HR $\leq$0.65 AND interim OS gain $\geq$20% (if OS is not mature)

Increase in 7-year survival alone $\geq$10% (if $>$20% patients have reached 7 years OS)

**GRADE 3**
HR $\leq$0.70 AND gain 8 - $<$12 months

HR $\leq$0.65 AND interim OS gain 10-20% (if OS is not mature)

**GRADE 2**
HR $\leq$0.70 AND gain 6 - $<$8 months

HR $>$0.70-$\leq$0.75 AND gain $\geq$6 months

HR $\leq$0.65 AND interim OS gain $<$10% (if OS is not mature)

**GRADE 1**
HR $>$0.75 OR gain $<$6 months

Preliminary magnitude of clinical benefit grade (highest grade scored) 4 3 2 1

HR, hazard ratio; OS, overall survival


**Quality of Life assessment**

Does secondary endpoint quality of life show improvement or delayed deterioration in quality of life

---

**Adjustments**

01. Upgrade 1 level if improved quality of life and/or less grade 3-4 toxicities impacting daily well-being are shown

02. If there is a long-term plateau in the survival curve, and OS advantage continues to be observed at 10 years, also score according to form 1a (treatments with curative potential) and present both scores i.e. A/4

---

<table>
<thead>
<tr>
<th>Final adjusted magnitude of clinical benefit grade</th>
<th>5</th>
<th>4</th>
<th>3</th>
<th>2</th>
<th>1</th>
</tr>
</thead>
</table>

Non-curative setting grading 5 and 4 indicates a substantial magnitude of clinical benefit